US5922253A
(en)
*
|
1995-05-18 |
1999-07-13 |
Alkermes Controlled Therapeutics, Inc. |
Production scale method of forming microparticles
|
US5989463A
(en)
*
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
US6723517B1
(en)
*
|
1998-06-02 |
2004-04-20 |
Minerva Biotechnologies Corporation |
Use of self-assembled monolayers to probe the structure of a target molecule
|
US6387410B1
(en)
|
1998-09-10 |
2002-05-14 |
Norton Healthcare Ltd |
Anti-inflammatory pharmaceutical formulations
|
US6514525B2
(en)
|
1998-09-10 |
2003-02-04 |
Norton Healthcare Ltd |
Anti-inflammatory pharmaceutical formulations
|
EP1074248A1
(en)
*
|
1999-07-08 |
2001-02-07 |
Arnold Hilgers |
Delivery system for biological material
|
US6458387B1
(en)
*
|
1999-10-18 |
2002-10-01 |
Epic Therapeutics, Inc. |
Sustained release microspheres
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
WO2001055217A1
(en)
|
2000-01-27 |
2001-08-02 |
Medimmune, Inc. |
Ultra high affinity neutralizing antibodies
|
JP2003525061A
(en)
*
|
2000-03-01 |
2003-08-26 |
メディミューン,インコーポレイテッド |
High potency recombinant antibody and method for producing the same
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
KR100867392B1
(en)
*
|
2000-08-15 |
2008-11-06 |
더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 |
Microparticles
|
US6824822B2
(en)
*
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US7666445B2
(en)
|
2000-10-20 |
2010-02-23 |
The Trustees Of The University Of Pennsylvania |
Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
|
US7374782B2
(en)
|
2000-10-27 |
2008-05-20 |
Baxter International Inc. |
Production of microspheres
|
US6818216B2
(en)
*
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
JP4434580B2
(en)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
Methods for administering / prescribing anti-RSV antibodies for prevention and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
EP2354149B1
(en)
|
2000-12-12 |
2017-08-30 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
US20030044406A1
(en)
*
|
2001-03-02 |
2003-03-06 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
|
US6730772B2
(en)
|
2001-06-22 |
2004-05-04 |
Venkatram P. Shastri |
Degradable polymers from derivatized ring-opened epoxides
|
ES2307779T3
(en)
*
|
2001-08-16 |
2008-12-01 |
Baxter International Inc. |
FORMULATIONS OF PROPELLENT-BASED MICROPARTICLES.
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
US8685427B2
(en)
|
2002-07-31 |
2014-04-01 |
Boston Scientific Scimed, Inc. |
Controlled drug delivery
|
US8133501B2
(en)
|
2002-02-08 |
2012-03-13 |
Boston Scientific Scimed, Inc. |
Implantable or insertable medical devices for controlled drug delivery
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
AU2003256823B9
(en)
*
|
2002-07-25 |
2009-01-08 |
Medimmune, Llc |
Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
|
US8920826B2
(en)
|
2002-07-31 |
2014-12-30 |
Boston Scientific Scimed, Inc. |
Medical imaging reference devices
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
EP2298806A1
(en)
|
2002-10-16 |
2011-03-23 |
Purdue Pharma L.P. |
Antibodies that bind cell-associated CA 125/0722P and methods of use thereof
|
US6800663B2
(en)
*
|
2002-10-18 |
2004-10-05 |
Alkermes Controlled Therapeutics Inc. Ii, |
Crosslinked hydrogel copolymers
|
KR100709015B1
(en)
*
|
2002-11-13 |
2007-04-18 |
(주)아모레퍼시픽 |
Polymeric microparticulates for sustained release of drug and their preparation methods
|
BRPI0406628A
(en)
|
2003-01-06 |
2005-12-06 |
Corixa Corp |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1596804A4
(en)
|
2003-01-13 |
2008-02-06 |
Macrogenics Inc |
SOLUBLE FcyR FUSION PROTEINS AND METHODS OF USE THEREOF
|
US7658998B2
(en)
*
|
2003-01-22 |
2010-02-09 |
Alkermes Controlled Therapeutics, Inc. |
Method of preparing sustained release microparticles
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
SI2656854T1
(en)
|
2003-02-04 |
2015-09-30 |
Cornell Research Foundation, Inc. |
Uses of aromatic-cationic peptide
|
US7736391B2
(en)
|
2003-02-06 |
2010-06-15 |
Tonaba Healthscience Ii, Llc |
Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
|
JP2006521367A
(en)
*
|
2003-03-26 |
2006-09-21 |
株式会社Lttバイオファーマ |
Nanoparticles for intravenous injection for targeting and sustained release
|
KR20110094361A
(en)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
Recombinant il-9 antibodies and uses thereof
|
KR101161823B1
(en)
|
2003-05-01 |
2012-07-03 |
코넬 리서치 화운데이션,인크. |
Method and carrier complexes for delivering molecules to cells
|
US7326571B2
(en)
*
|
2003-07-17 |
2008-02-05 |
Boston Scientific Scimed, Inc. |
Decellularized bone marrow extracellular matrix
|
US20070092452A1
(en)
*
|
2003-07-18 |
2007-04-26 |
Julia Rashba-Step |
Methods for fabrication, uses, compositions of inhalable spherical particles
|
US20050142205A1
(en)
*
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
MXPA06000720A
(en)
*
|
2003-07-18 |
2006-08-23 |
Baxter Int |
Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation.
|
EP1646354A4
(en)
*
|
2003-07-22 |
2010-03-17 |
Baxter Int |
Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
DK1677735T3
(en)
|
2003-10-17 |
2014-10-27 |
Joslin Diabetes Center Inc |
METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION
|
US7309500B2
(en)
*
|
2003-12-04 |
2007-12-18 |
The Board Of Trustees Of The University Of Illinois |
Microparticles
|
US20060053516A1
(en)
*
|
2003-12-05 |
2006-03-09 |
The University Of Hong Kong |
Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS
|
WO2005058961A2
(en)
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
US8329203B2
(en)
|
2004-01-12 |
2012-12-11 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
US8221778B2
(en)
|
2005-01-12 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
WO2005072702A2
(en)
*
|
2004-01-20 |
2005-08-11 |
Alkermes Controlled Therapeutics, Inc. |
Method for milling frozen microparticles
|
NZ549393A
(en)
|
2004-01-23 |
2009-07-31 |
Cornell Res Foundation Inc |
Methods for reducing oxidative damage
|
WO2005110425A1
(en)
|
2004-04-15 |
2005-11-24 |
Alkermes, Inc. |
Polymer-based sustained release device
|
ES2313350T3
(en)
|
2004-05-12 |
2009-03-01 |
Baxter International Inc. |
MICROSPHERAS OF NUCLEIC ACID, PRODUCTION AND SUPPLY OF THE SAME.
|
CA2566075A1
(en)
|
2004-05-12 |
2005-12-01 |
Baxter Healthcare S.A. |
Microspheres comprising protein and showing injectability at high concentrations of said agent
|
AU2005244851B2
(en)
|
2004-05-12 |
2010-08-26 |
Baxter Healthcare S.A. |
Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
|
US8728525B2
(en)
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
US9006181B2
(en)
|
2004-07-21 |
2015-04-14 |
The Administrators Of The Tulane Educational Fund |
Treatment of renal dysfunction and multiple myeloma using PACAP compounds
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
JP2008518936A
(en)
*
|
2004-10-29 |
2008-06-05 |
メディミューン,インコーポレーテッド |
Methods for preventing and treating RSV infections and related conditions
|
US7748343B2
(en)
|
2004-11-22 |
2010-07-06 |
The Board Of Trustees Of The University Of Illinois |
Electrohydrodynamic spraying system
|
US20060165667A1
(en)
*
|
2004-12-03 |
2006-07-27 |
Case Western Reserve University |
Novel methods, compositions and devices for inducing neovascularization
|
WO2006078841A1
(en)
*
|
2005-01-21 |
2006-07-27 |
President And Fellows Of Harvard College |
Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
ES2707152T3
(en)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
JP2008539260A
(en)
*
|
2005-04-25 |
2008-11-13 |
アムジエン・インコーポレーテツド |
Biodegradable ptide sustained-release composition containing porogen
|
US8017152B2
(en)
|
2005-05-27 |
2011-09-13 |
Stratosphere Pharma Ab |
Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CN101379085B
(en)
*
|
2005-06-30 |
2013-03-27 |
Abbvie公司 |
IL-12/P40 binding proteins
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
WO2007024715A2
(en)
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CN103784937B
(en)
|
2005-09-16 |
2017-04-26 |
科内尔研究基金会 |
Methods for reducing CD36 expression
|
CA2624562A1
(en)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
US8691224B2
(en)
|
2005-11-30 |
2014-04-08 |
Abbvie Inc. |
Anti-Aβ globulomer 5F7 antibodies
|
KR20180058863A
(en)
|
2005-11-30 |
2018-06-01 |
애브비 인코포레이티드 |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
US8916206B2
(en)
*
|
2005-12-26 |
2014-12-23 |
Ltt Bio-Pharma Co., Ltd. |
Nanoparticles containing water-soluble non-peptide low-molecular weight drug
|
EP2198863A1
(en)
|
2006-02-27 |
2010-06-23 |
The Johns Hopkins University |
Cancer treatment with gamma-secretase inhibitors
|
US8747870B2
(en)
|
2006-04-20 |
2014-06-10 |
University Of Utah Research Foundation |
Polymeric compositions and methods of making and using thereof
|
EP2012803A4
(en)
*
|
2006-04-20 |
2012-08-01 |
Univ Utah Res Found |
Polymeric compositions and methods of making and using thereof
|
US20070281031A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Guohan Yang |
Microparticles and methods for production thereof
|
EP2037961B1
(en)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
ES2599319T3
(en)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Fc RIIB specific antibodies and their methods of use
|
US20080075777A1
(en)
*
|
2006-07-31 |
2008-03-27 |
Kennedy Michael T |
Apparatus and methods for preparing solid particles
|
AU2007281737B2
(en)
|
2006-08-04 |
2013-09-19 |
Baxter Healthcare S.A. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
PL2359808T3
(en)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotic delivery systems and piston assemblies
|
EP2064243A2
(en)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
CA3007075C
(en)
|
2006-09-07 |
2019-10-15 |
Arthur E. Frankel |
Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
|
MY188368A
(en)
|
2006-09-08 |
2021-12-06 |
Abbott Lab |
Interleukin-13 binding proteins
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
US20080121733A1
(en)
*
|
2006-11-29 |
2008-05-29 |
Donald Ackley |
Droplet generating device and method
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
MX2009006653A
(en)
|
2006-12-18 |
2009-07-02 |
Takeda Pharmaceutical |
Sustained-release composition and method for producing the same.
|
US20100190920A1
(en)
*
|
2007-02-14 |
2010-07-29 |
Anuj Bellare |
Crosslinked polymers and methods of making the same
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
MX2009011123A
(en)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Suspension formulations of insulinotropic peptides and uses thereof.
|
WO2008134807A1
(en)
*
|
2007-05-04 |
2008-11-13 |
The University Of Sydney |
Method for manufacturing a porous polymer matrix
|
EP2156848A4
(en)
*
|
2007-05-14 |
2012-11-28 |
Ltt Bio Pharma Co Ltd |
Low-molecule drug-containing nanoparticle having sustained release negatively charged group
|
US20090175847A1
(en)
*
|
2007-05-30 |
2009-07-09 |
Abbott Laboratories |
Humanized antibodies to ab (20-42) globulomer and uses thereof
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
EP2069401A4
(en)
|
2007-07-31 |
2011-02-23 |
Medimmune Llc |
Multispecific epitope binding proteins and uses thereof
|
JP5502751B2
(en)
|
2007-12-20 |
2014-05-28 |
エボニック コーポレイション |
Process for preparing microparticles with low residual solvent concentration
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
CN101939019B
(en)
|
2008-02-07 |
2014-07-16 |
康奈尔大学 |
Methods for preventing or treating insulin resistance
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
EP2262520B1
(en)
|
2008-02-26 |
2017-05-03 |
Cornell University |
Compositions for prevention and treatment of renal injury
|
EP2698173A1
(en)
*
|
2008-02-29 |
2014-02-19 |
Coloplast A/S |
Compositions and methods for augmentation and regeneration of living tissue in a subject
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
CN102083969A
(en)
|
2008-05-06 |
2011-06-01 |
乔斯林糖尿病中心股份有限公司 |
Methods and compositions for inducing brown adipogenesis
|
WO2009136382A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
KR20110016959A
(en)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
Dual variable domain immunoglobulins and uses thereof
|
JP2011523853A
(en)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
Dual variable domain immunoglobulins and uses thereof
|
ES2770273T3
(en)
*
|
2008-06-27 |
2020-07-01 |
Tepha Inc |
Injectable administration of microparticles and compositions therefor
|
SG192489A1
(en)
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
RU2559525C2
(en)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Proteins binding prostaglandin e2 and using them
|
US8367427B2
(en)
|
2008-08-20 |
2013-02-05 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US8323615B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing multi-phasic dispersions
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US20110218155A1
(en)
|
2008-10-10 |
2011-09-08 |
Dana-Farber Cancer Institute, Inc. |
Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
|
US20110212179A1
(en)
*
|
2008-10-30 |
2011-09-01 |
David Liu |
Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
|
EP2358748B1
(en)
|
2008-12-09 |
2016-07-06 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for specific modulation of mcl-1
|
JP5734201B2
(en)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and use thereof
|
WO2010085607A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Surmodics Pharmaceuticals, Inc. |
Continuous double emulsion process for making microparticles
|
RU2011135768A
(en)
*
|
2009-01-29 |
2013-03-10 |
Эбботт Лэборетриз |
PROTEINS BINDING IL-1
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US8030026B2
(en)
*
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
PE20121094A1
(en)
|
2009-03-05 |
2012-09-13 |
Abbvie Inc |
IL-17 BINDING PROTEINS
|
US8283162B2
(en)
*
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
CN103933542A
(en)
|
2009-03-20 |
2014-07-23 |
通用医疗公司以马萨诸塞州通用医疗公司名义经营 |
Methods For The Prevention And Treatment Of Burn Injuries And Secondary Complications
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
JP5762408B2
(en)
|
2009-08-13 |
2015-08-12 |
クルセル ホランド ベー ヴェー |
Antibodies against human respiratory syncytial virus (RSV) and methods of use
|
SI3708178T1
(en)
|
2009-08-24 |
2024-01-31 |
Stealth Biotherapeutics Inc. |
Peptide for use in preventing or treating macular degeneration
|
EP2470568A2
(en)
|
2009-08-29 |
2012-07-04 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
SG178602A1
(en)
*
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
NZ598686A
(en)
|
2009-09-28 |
2014-05-30 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
EP2485749A4
(en)
|
2009-10-05 |
2013-07-24 |
Univ Cornell |
Methods for the prevention or treatment of heart failure
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
JP5898082B2
(en)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
|
BR112012008833A2
(en)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
double variable domain immunoglobulins and uses thereof
|
UY32979A
(en)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
CA2779496A1
(en)
|
2009-11-02 |
2011-05-05 |
The Administrators Of The Tulane Educational Fund |
Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
US20130190244A1
(en)
|
2009-12-31 |
2013-07-25 |
Stealth Peptides International, Inc. |
Methods for performing a coronary artery bypass graft procedure
|
EP3090754A1
(en)
|
2009-12-31 |
2016-11-09 |
Stealth Peptides International, Inc. |
Methods for the prevention or treatment of vessel occlusion injury
|
CN102834408A
(en)
|
2010-01-25 |
2012-12-19 |
康奈尔大学 |
Aromatic-cationic peptides and uses of same
|
CA2790823A1
(en)
|
2010-02-26 |
2011-09-01 |
University Of Florida Research Foundation, Inc. |
Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
EP3210615A1
(en)
|
2010-03-15 |
2017-08-30 |
Stealth Peptides International, Inc. |
Combination therapies using cyclosporine and aromatic cationic peptides
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
EP2942354A1
(en)
|
2010-05-03 |
2015-11-11 |
Stealth Peptides International, Inc. |
Aromatic-Cationic Peptides and Uses of Same
|
ES2659406T3
(en)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6)
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
UY33386A
(en)
|
2010-05-14 |
2011-12-30 |
Abbott Laboratoires |
IL-1 UNION PROTEINS
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
CN103097412B
(en)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
Anti-human respiratory syncytial virus (RSV) antibody and using method
|
UY33492A
(en)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
EP4285994A3
(en)
|
2010-07-09 |
2024-01-17 |
Stealth BioTherapeutics Inc. |
Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
CN103154025B
(en)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
Covalent diabodies and uses thereof
|
MX341579B
(en)
|
2010-08-03 |
2016-08-25 |
Abbvie Inc * |
Dual variable domain immunoglobulins and uses thereof.
|
CN103298833B
(en)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
Amyloid beta associated proteins
|
PL3333188T3
(en)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Anti-ngf antibodies and their use
|
CN103080134B
(en)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
The antibody of EGF-R ELISA 3 (HER3)
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012050673A1
(en)
|
2010-10-14 |
2012-04-19 |
Wisconsin Alumni Research Foundation |
Methods for the treatment of x-linked hypophosphatemia and related disorders
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
TW201307388A
(en)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
IL-1 binding proteins
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN103796665B
(en)
|
2011-03-24 |
2018-10-30 |
康奈尔大学 |
Aromatic-cationic peptides and application thereof
|
RU2625034C2
(en)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Antibodies and other molecules binding b7-h1 and pd-1
|
MX347818B
(en)
|
2011-05-21 |
2017-05-15 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life.
|
KR20140061403A
(en)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
WO2013027191A1
(en)
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
EP2758434A2
(en)
|
2011-09-23 |
2014-07-30 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Anti-tumor necrosis factor-alpha agents and uses thereof
|
CN107496899A
(en)
|
2011-09-29 |
2017-12-22 |
梅约医学教育与研究基金会 |
Aromatic-cationic peptide and use their method
|
CN107261380A
(en)
|
2011-10-17 |
2017-10-20 |
康奈尔大学 |
Aromatic-cationic peptides and application thereof
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
JP6243345B2
(en)
|
2011-12-05 |
2017-12-06 |
ノバルティス アーゲー |
Antibody to epidermal growth factor receptor 3 (HER3)
|
KR20140103135A
(en)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EP3466439A1
(en)
|
2011-12-09 |
2019-04-10 |
Stealth Peptides International, Inc. |
Aromatic-cationic peptides and uses of same
|
WO2013090635A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
WO2013090633A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
NZ625403A
(en)
|
2012-01-27 |
2016-03-31 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
US20150018288A1
(en)
|
2012-02-22 |
2015-01-15 |
Stealth Peptides International, Inc. |
Methods and compositions for preventing or treating ophthalmic conditions
|
AU2013222237B2
(en)
|
2012-02-23 |
2017-10-05 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
SG11201405553YA
(en)
|
2012-03-08 |
2014-11-27 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
US9585970B2
(en)
|
2012-06-04 |
2017-03-07 |
Novartis Ag |
Site-specific labeling methods and molecules produced thereby
|
JP6629069B2
(en)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
Canine anti-NGF antibody and method thereof
|
UY34905A
(en)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
IL-1 UNION PROTEINS
|
EP3662921A1
(en)
|
2012-08-02 |
2020-06-10 |
Stealth Peptides International, Inc. |
D-arg-2'6'-dmt-lys-phe-nh2 for decreasing statin side effects
|
PE20151434A1
(en)
|
2012-10-22 |
2015-10-16 |
Stealth Peptides Int Inc |
METHODS FOR THE REDUCTION OF RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED WITH IT
|
TW202210507A
(en)
|
2012-11-01 |
2022-03-16 |
美商艾伯維有限公司 |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
BR112015010722A2
(en)
|
2012-11-09 |
2017-08-22 |
Pfizer |
SPECIFIC GROWTH FACTOR ANTIBODIES DERIVED FROM ISOFORM B PLATELETS AND COMPOSITIONS AND USES THEREOF
|
WO2014088631A1
(en)
|
2012-12-06 |
2014-06-12 |
Stealth Peptides International, Inc. |
Peptide therapeutics and methods for using same
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
BR112015014621A2
(en)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
ANTI-H7CR ANTIBODIES
|
AU2014214751B2
(en)
|
2013-02-08 |
2017-06-01 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
DK2961378T3
(en)
|
2013-03-01 |
2019-11-25 |
Stealth Biotherapeutics Corp |
METHODS OF TREATING MITOCHONDRIC DISEASE
|
CN115990242A
(en)
|
2013-03-01 |
2023-04-21 |
康德生物医疗有限公司 |
Methods and compositions for preventing or treating Bass syndrome
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
WO2014143342A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
BR112015023239A8
(en)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
hcv antibody-antigen combination assay and methods and compositions for use thereof
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
CN105007950B
(en)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
Antibody drug conjugate
|
EP3586864A1
(en)
|
2013-05-14 |
2020-01-01 |
Stealth Biotherapeutics Corp |
Methods for the prevention or treatment of left ventricle remodeling
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
ES2753419T3
(en)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Complement factor H inhibitors
|
CA2916977A1
(en)
|
2013-06-26 |
2014-12-31 |
Stealth Biotherapeutics Corp |
Methods and compositions for detecting and diagnosing diseases and conditions
|
US9884085B2
(en)
|
2013-06-26 |
2018-02-06 |
Stealth Biotherapeutics Corp |
Methods for the regulation of matrix metalloproteinase expression
|
CA2916486A1
(en)
|
2013-06-26 |
2015-01-22 |
Stealth Biotherapeutics Corp |
Methods and compositions comprising an aromatic peptide for regulating serca2a expression levels in myocardinal infarction
|
US10293020B2
(en)
|
2013-06-27 |
2019-05-21 |
Stealth Biotherapeutics Corp. |
Peptide therapeutics and methods for using same
|
CA2920020C
(en)
|
2013-08-02 |
2023-03-14 |
Stealth Biotherapeutics Corp |
Methods and compositions for the prevention and treatment of friedreich's ataxia
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(en)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
CN105764924A
(en)
|
2013-09-12 |
2016-07-13 |
哈洛齐梅公司 |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
KR20160055275A
(en)
|
2013-09-17 |
2016-05-17 |
유니버시티 헬스 네트워크 |
Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in the methods of treatment
|
WO2015058868A1
(en)
|
2013-10-25 |
2015-04-30 |
Pangaea Biotech, S.L. |
Compositions and methods for the treatment of cancer
|
WO2015066480A1
(en)
|
2013-11-01 |
2015-05-07 |
Regents Of The University Of Minnesota |
Protein scaffolds and methods of use
|
KR102366076B1
(en)
|
2013-11-13 |
2022-02-21 |
화이자 인코포레이티드 |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
TW201536320A
(en)
|
2013-12-02 |
2015-10-01 |
Abbvie Inc |
Compositions and methods for treating osteoarthritis
|
CN105939759B
(en)
|
2013-12-02 |
2020-01-17 |
康德生物医疗技术公司 |
Compositions and methods for treating vitiligo
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
EP3738981A1
(en)
|
2014-01-24 |
2020-11-18 |
NGM Biopharmaceuticals, Inc. |
Antibodies binding beta klotho domain 2 and methods of use thereof
|
CA2939556A1
(en)
|
2014-02-14 |
2015-08-20 |
Andrew S. Chi |
Improved methods for the treatment of vascularizing cancers
|
EP3450571B1
(en)
|
2014-02-24 |
2023-04-05 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
BR112016020065A2
(en)
|
2014-03-12 |
2018-02-20 |
Novartis Ag |
specific sites to modify antibodies to make immunoconjugates
|
KR20220025946A
(en)
|
2014-03-21 |
2022-03-03 |
애브비 인코포레이티드 |
Anti-egfr antibodies and antibody drug conjugates
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
EP3148565A4
(en)
|
2014-05-28 |
2018-06-06 |
Stealth Biotherapeutics Corp |
Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
|
CA2950410A1
(en)
|
2014-05-28 |
2015-12-03 |
D. Travis Wilson |
Therapeutic compositions including therapeutic small molecules and uses thereof
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
US9668996B2
(en)
|
2014-06-04 |
2017-06-06 |
Tersus Life Sciences, LLC |
Methods of treating chronic dry eye disease using C16:1n7-palmitoleate and derivatives thereof
|
WO2015195737A1
(en)
|
2014-06-17 |
2015-12-23 |
Stealth Peptides International, Inc. |
Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
|
TWI693232B
(en)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
|
CN107257691B
(en)
|
2014-07-16 |
2021-09-21 |
达娜-法勃肿瘤研究所公司 |
HER3 inhibition in low-grade serous ovarian cancer
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
PE20170903A1
(en)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
|
EP3903802A1
(en)
|
2014-08-21 |
2021-11-03 |
Stealth Biotherapeutics Corp |
Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
|
UY36316A
(en)
|
2014-09-26 |
2016-04-29 |
Macrogenics Inc |
MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN CD19 AND CD3, AND USES OF THE SAME
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
WO2016075670A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
US10654909B2
(en)
|
2014-12-04 |
2020-05-19 |
Novartis Ag |
Soluble alpha klotho and serum albumin fusion protein
|
WO2016183532A1
(en)
|
2015-05-13 |
2016-11-17 |
Synlogic, Inc. |
Bacteria engineered to treat a disease or disorder
|
SG10202010444UA
(en)
|
2014-12-05 |
2020-11-27 |
Synlogic Operating Co Inc |
Bacteria engineered to treat diseases associated with hyperammonemia
|
US9688967B2
(en)
|
2014-12-05 |
2017-06-27 |
Synlogic, Inc. |
Bacteria engineered to treat diseases associated with hyperammonemia
|
ES2894034T3
(en)
|
2014-12-05 |
2022-02-11 |
Synlogic Operating Co Inc |
Modified bacteria to treat diseases associated with hyperammonemia
|
KR20170087500A
(en)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
Anti-C10ORF54 antibodies and uses thereof
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
WO2016118921A1
(en)
|
2015-01-24 |
2016-07-28 |
Abbvie, Inc. |
Compositions and methods for treating psoriatic arthritis
|
KR20170105622A
(en)
|
2015-01-26 |
2017-09-19 |
마크로제닉스, 인크. |
A multivalent molecule comprising a DR5-binding domain
|
WO2016120828A1
(en)
|
2015-01-30 |
2016-08-04 |
Novartis Ag |
Treatment of breast cancer by m-csf antagonist
|
CN107636146A
(en)
|
2015-03-02 |
2018-01-26 |
同生公司 |
It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up
|
FI3265123T3
(en)
|
2015-03-03 |
2023-01-31 |
|
Antibodies, uses & methods
|
JP6843768B2
(en)
|
2015-05-13 |
2021-03-17 |
シンロジック オペレーティング カンパニー インコーポレイテッド |
Bacteria engineered to reduce hyperphenylalanineemia
|
EP3303395B1
(en)
|
2015-05-29 |
2019-12-11 |
AbbVie Inc. |
Anti-cd40 antibodies and uses thereof
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
TWI773646B
(en)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
Lag-3-binding molecules and methods of use thereof
|
AU2016274311A1
(en)
|
2015-06-10 |
2018-01-18 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases associated with hyperammonemia
|
TW201710286A
(en)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
Binding proteins against VEGF, PDGF, and/or their receptors
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
WO2016210373A2
(en)
|
2015-06-24 |
2016-12-29 |
Synlogic, Inc. |
Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
LT3328419T
(en)
|
2015-07-30 |
2021-11-10 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods of use thereof
|
AU2016303662A1
(en)
|
2015-07-31 |
2018-02-22 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat disorders involving propionate catabolism
|
US11331191B2
(en)
|
2015-08-12 |
2022-05-17 |
Howmedica Osteonics Corp. |
Bioactive soft tissue implant and methods of manufacture and use thereof
|
CA2938576A1
(en)
*
|
2015-08-12 |
2017-02-12 |
Howmedica Osteonics Corp. |
Methods for forming scaffolds
|
WO2017040719A1
(en)
|
2015-08-31 |
2017-03-09 |
Synlogic, Inc. |
Bacteria engineered to treat disorders in which oxalate is detrimental
|
CN108473576A
(en)
|
2015-09-11 |
2018-08-31 |
艾伯维公司 |
Method for the multiple sclerosis for treating recurrence form
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
CA2997963A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
WO2017059338A1
(en)
|
2015-10-02 |
2017-04-06 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
US10138298B2
(en)
|
2015-10-23 |
2018-11-27 |
The Regents Of The University Of California |
Anti-IL-2 antibodies and compositions and uses thereof
|
AU2016346646B2
(en)
|
2015-10-30 |
2022-12-01 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
WO2017075485A1
(en)
|
2015-10-30 |
2017-05-04 |
Synlogic, Inc. |
Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
|
US11685925B2
(en)
|
2015-10-30 |
2023-06-27 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
EP3377518B1
(en)
|
2015-11-16 |
2022-04-13 |
Synlogic Operating Company, Inc. |
Bacteria engineered to reduce hyperphenylalaninemia
|
ES2861449T3
(en)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses
|
KR20180100122A
(en)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
|
EP3389714A4
(en)
|
2015-12-14 |
2019-11-13 |
MacroGenics, Inc. |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
CN116196388A
(en)
|
2016-01-06 |
2023-06-02 |
康德生物医疗有限公司 |
Methods and compositions for preventing and treating duchenne muscular dystrophy
|
WO2017123610A2
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Bacteria engineered to detoxify deleterious molecules
|
WO2017123592A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Bacteria engineered to treat disorders associated with bile salts
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
AU2017211214A1
(en)
*
|
2016-01-25 |
2018-07-12 |
Smith & Nephew, Inc. |
Orthopaedic implant
|
EP3241571B1
(en)
|
2016-05-02 |
2020-07-22 |
Howmedica Osteonics Corporation |
Bioactive soft tissue implant and methods of manufacture and use thereof
|
CN109310743A
(en)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
Glucagon receptor selectivity polypeptide and its application method
|
EP3458159A4
(en)
|
2016-05-19 |
2019-12-18 |
Stealth BioTherapeutics Corp |
Compositions and methods for the prevention and treatment of mitochondrial myopathies
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
JP2019526529A
(en)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
Anti-B7-H3 antibody and antibody drug conjugate
|
PE20190177A1
(en)
|
2016-06-08 |
2019-02-01 |
Abbvie Inc |
ANTI-B7-H3 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES
|
CN109562169A
(en)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
Anti-CD 98 antibody and antibody drug conjugates
|
US11567082B2
(en)
|
2016-07-01 |
2023-01-31 |
Dana-Farber Cancer Institute, Inc. |
Compositions, assays, and methods for direct modulation of fatty acid metabolism
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
JP2019534859A
(en)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Method for treating vitiligo using PD-1 binding protein
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
EP3544628A4
(en)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
EP3565580B1
(en)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
|
JOP20190187A1
(en)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
Anti-ccr7 antibody drug conjugates
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
KR20200026209A
(en)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
|
IL271085B1
(en)
|
2017-06-21 |
2024-03-01 |
Synlogic Operating Co Inc |
Bacteria for the treatment of disorders
|
MX2020001546A
(en)
|
2017-08-08 |
2020-08-03 |
Memorial Sloan Kettering Cancer Center |
Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor.
|
WO2019048930A2
(en)
|
2017-09-08 |
2019-03-14 |
Keio University |
Bacteriophage for modulating inflammatory bowel disease
|
WO2019106578A2
(en)
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
MX2020005662A
(en)
|
2017-12-01 |
2020-08-20 |
Pfizer |
Anti-cxcr5 antibodies and compositions and uses thereof.
|
EP3765499A1
(en)
|
2018-03-12 |
2021-01-20 |
Zoetis Services LLC |
Anti-ngf antibodies and methods thereof
|
MX2020010183A
(en)
|
2018-03-29 |
2022-11-28 |
Pfizer |
Lfa3 variants and compositions and uses thereof.
|
US10633458B2
(en)
|
2018-04-10 |
2020-04-28 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
EP3801766A1
(en)
|
2018-05-31 |
2021-04-14 |
Novartis AG |
Hepatitis b antibodies
|
PE20210320A1
(en)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
|
EP3824287A1
(en)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Receptor for vista
|
BR112021004287A2
(en)
|
2018-09-07 |
2021-08-03 |
Pfizer Inc. |
anti-avss8 antibodies and compositions and uses thereof
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
ES2961003T3
(en)
|
2018-12-06 |
2024-03-07 |
Stealth Biotherapeutics Inc |
D-Arg-2'6'-Dmt-Lys-Phe-NH2 for use in the treatment or prevention of Sengers syndrome
|
WO2020128863A1
(en)
|
2018-12-19 |
2020-06-25 |
Novartis Ag |
Anti-tnf-alpha antibodies
|
PE20211296A1
(en)
|
2018-12-21 |
2021-07-20 |
Novartis Ag |
ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
|
AU2020231609A1
(en)
|
2019-03-07 |
2021-10-28 |
Biomx Ltd. |
Bacteriophage for modulating inflammatory bowel disease
|
CA3132959A1
(en)
|
2019-03-08 |
2020-09-17 |
AbTis Co., Ltd. |
Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof
|
TW202102526A
(en)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
Recombinant adeno-associated viruses and uses thereof
|
US20220257732A1
(en)
|
2019-04-29 |
2022-08-18 |
Synlogic Operating Company, Inc. |
Enumeration of genetically engineered microorganisms by live cell counting techniques
|
US11518877B2
(en)
*
|
2019-05-07 |
2022-12-06 |
Ut-Battelle, Llc |
Toughened polyester composites containing polyester matrix and droplets of high boiling liquid therein
|
GB2598520A
(en)
|
2019-05-28 |
2022-03-02 |
Univ Shanghai Tech |
Composition and methods to treat ectodermal dysplasia 2, Clouston type
|
CN114466656A
(en)
|
2019-07-24 |
2022-05-10 |
康德生物医疗有限公司 |
Peptidomimetic compounds (R) -2-amino-N- ((S) -1- (((S) -5-amino-1- (3-benzyl-1, 2, 4-oxadiazol-5-yl) pentyl) amino) -3- (4-hydroxy-2, 6-xylyl) -1-oxopropan-2-yl) -5-guanidinopentanamide in the treatment of neurodegenerative disorders
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
TW202126317A
(en)
|
2019-09-24 |
2021-07-16 |
美商普拉塔生技公司 |
Compositions and methods for treatment of inflammatory and immune diseases
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
CN114746430A
(en)
|
2019-10-04 |
2022-07-12 |
康德生物医疗有限公司 |
Quinone-, hydroquinone-and naphthoquinone-analogues of vattinoquinone for the treatment of mitochondrial disorders
|
JP2022552282A
(en)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
Antibodies specific for glycosylated LAG3 and methods of use thereof
|
CA3166528A1
(en)
|
2020-03-20 |
2021-09-23 |
Kristin ADOLFSEN |
Microorganisms engineered to reduce hyperphenylalaninemia
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
AU2021246142A1
(en)
|
2020-04-03 |
2022-10-20 |
Stealth Biotherapeutics Inc. |
Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
US20230167193A1
(en)
|
2020-05-01 |
2023-06-01 |
Novartis Ag |
Immunoglobulin variants
|
WO2022076711A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
CN116472288A
(en)
|
2020-11-06 |
2023-07-21 |
诺华股份有限公司 |
Antibody Fc variants
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
CN116670269A
(en)
|
2020-12-02 |
2023-08-29 |
同生运营公司 |
Engineered microorganisms
|
WO2022146718A1
(en)
|
2020-12-31 |
2022-07-07 |
Synlogic Operating Company, Inc. |
Microorganisms engineered to reduce hyperphenylalaninemia
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
MX2023008227A
(en)
|
2021-01-12 |
2023-07-20 |
Prolacta Bioscience Inc |
Synbiotic treatment regimens.
|
AR124681A1
(en)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
ANTI-EGFR ANTIBODY-DRUG CONJUGATES
|
WO2022221273A1
(en)
|
2021-04-13 |
2022-10-20 |
Synlogic Operating Company, Inc. |
Bacteria engineered to secrete active proteins
|
BR112023021475A2
(en)
|
2021-04-16 |
2023-12-19 |
Novartis Ag |
ANTIBODY-DRUG CONJUGATES AND METHODS FOR PRODUCING THEM
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
WO2023044479A1
(en)
|
2021-09-17 |
2023-03-23 |
Synlogic Operating Company, Inc. |
Methods for reducing hyperphenylalaninemia
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023069255A1
(en)
|
2021-10-20 |
2023-04-27 |
Stealth Biotherapeutics Inc. |
Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
WO2023101963A2
(en)
|
2021-11-30 |
2023-06-08 |
Northwestern University |
Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023133321A1
(en)
|
2022-01-10 |
2023-07-13 |
Stealth Biotherapeutics Inc. |
Small molecule peptidomimetic for the treatment of tauopathies
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
WO2023152633A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
|
TW202346590A
(en)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
Modified muscle-specific promoters
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023232976A1
(en)
|
2022-06-03 |
2023-12-07 |
Ags Therapeutics Sas |
Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
|
WO2023245171A1
(en)
|
2022-06-17 |
2023-12-21 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
|
WO2023245168A1
(en)
|
2022-06-17 |
2023-12-21 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
|
WO2023250478A1
(en)
|
2022-06-23 |
2023-12-28 |
Synlogic Operating Company, Inc. |
Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024081768A1
(en)
|
2022-10-12 |
2024-04-18 |
Synlogic Operating Company, Inc. |
Bacteria engineered to produce active epidermal growth factor (egf) and their medical uses
|